Showing results (31-40 of 2,154) with videos related to
Sort By:
Pageof 216
Expert Opinion on Biological Therapy|August 21, 2018
Ipilimumab in combination with nivolumab for the treatment of renal cell carcinomaXin Gao, David F McDermottTrends in Molecular Medicine|September 8, 2007
From inflammasomes to fevers, crystals and hypertension: how basic research explains inflammatory diseasesMichael F McDermott, Jürg TschoppHematology/Oncology Clinics of North America|July 19, 2011
Immunotherapy for renal cell carcinomaJacalyn Rosenblatt, David F McDermottExpert Reviews in Molecular Medicine|October 12, 2005
The tumour necrosis factor receptor-associated periodic syndrome: current conceptsSilvia Stojanov, Michael F McDermottCurrent Opinion in Microbiology|May 30, 2001
Biocides, drug resistance and microbial evolutionD G White, P F McDermottExpert Review of Clinical Immunology|October 29, 2010
Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromesLeigh D Church, Michael F McDermottCancer Treatment Reviews|February 2, 2010
Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial dataDavid F McDermott, Daniel J GeorgeCancer Medicine|January 10, 2014
PD-1 as a potential target in cancer therapyDavid F McDermott, Michael B AtkinsCytokine & Growth Factor Reviews|August 30, 2014
TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and futureLisa M Sedger, Michael F McDermottJournal of Veterinary Pharmacology and Therapeutics|October 3, 2020
Predicting antimicrobial susceptibility from the bacterial genome: A new paradigm for one health resistance monitoringPatrick F McDermott, James J DavisPageof 216